Hot New Papers

These are some of the most recent exciting publications in the field of Histamine research

Ekaterini Tiligada, Madeleine Ennis
Histamine pharmacology: from Sir Henry Dale to the 21st century
read
Abdurakhmanova S, Chary K, Kettunen M, Sierra A, Panula P.
Behavioral and stereological characterization of Hdc KO mice: relation to Tourette syndrome.
J Comp Neurol. 2017 Jul 6. doi: 10.1002/cne.24279. [Epub ahead of print]
read
Szakacs Z1, Dauvilliers Y2, Mikhaylov V3, Poverennova I4, Krylov S5, Jankovic S6, Sonka K7, Lehert P8, Lecomte I9, Lecomte JM9, Schwartz JC10; HARMONY-CTP study group.
Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
Lancet Neurol. 2017 Mar;16(3):200-207.
read
Schneider EH, Seifert R.
Pharmacological Characterization of Human Histamine Receptors and Histamine Receptor Mutantsin the Sf9 Cell Expression System.
Handb Exp Pharmacol. 2017 Feb 24. doi: 10.1007/164_2016_124
read
Shan L, Bao AM,Swaab DF.
Changes in Histidine Decarboxylase, Histamine N-Methyltransferase and Histamine Receptors in Neuropsychiatric Disorders.
Handb Exp Pharmacol. 2017 Feb 24. doi: 10.1007/164_2016_125.
read
Pittenger C.
Histidine Decarboxylase Knockout Mice as a Model of the Pathophysiology of Tourette Syndrome and Related Conditions.
Handb Exp Pharmacol. 2017 Feb 24. doi: 10.1007/164_2016_127.
read
Gabelle A, Jaussent I, Hirtz C, Vialaret J, Navucet S, Grasselli C, Robert P, Lehmann S, Dauvilliers Y.
Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process.
Neurobiol Aging. 2017 Jan 18;53:59-66.
read
Chen J, Hong T, Ding S, Deng L, Abudupataer M, Zhang W, Tong M, Jia J, Gong H, Zou Y, Wang TC, Ge J, Yang X.
Aggravated myocardial infarction-induced cardiac remodeling and heart failure in histamine-deficient mice.
Sci Rep. 2017 Mar 8;7:44007. doi: 10.1038/srep44007.
read
Schwartzbach CJ, Grove RA, Brown R, Tompson D, Then Bergh F, Arnold DL.
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
J Neurol. 2016 Nov 25. [Epub ahead of print]
read
Hagenow S, Stasiak A, Ramsay RR, Stark H.
Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B.
Sci Rep. 2017 Jan 13;7:40541
read
Smolinska S, Groeger D, Perez NR, Schiavi E, Ferstl R, Frei R, Konieczna P, Akdis CA, Jutel M, OʼMahony L.
Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2016 Jul;22(7):1575-86.
read
Barcik W, Pugin B, Westermann P, Perez NR, Ferstl R, Wawrzyniak M, Smolinska S, Jutel M, Hessel EM, Michalovich D, Akdis CA, Frei R, O'Mahony L.
Histamine-secreting microbes are increased in the gut of adult asthma patients.
J Allergy Clin Immunol. 2016 Nov;138(5):1491-1494.
read
Alonso N, Zappia CD, Cabrera M, Davio CA, Shayo C, Monczor F, Fernández NC.
Physiological implications of biased signaling at histamine H2 receptors
Front Pharmacol. 2015 Mar 10;6:45.
read
Zappia CD Granja-Galeano G, Fernández N, Shayo C, Davio C, Fitzsimons CP, Monczor F.
Effects of histamine H1 receptor signaling on glucocorticoid receptor activity. Role of canonical and non-canonical pathways.
Sci Rep. 2015 Dec 4;5:17476.
read
Monczor F, Fernandez N.
Current Knowledge and Perspectives on Histamine H1 and H2 Receptor Pharmacology: Functional Selectivity, Receptor Crosstalk, and Repositioning of Classic Histaminergic Ligands.
Mol Pharmacol. 2016 Nov;90(5):640-648.
read
Schwartzbach C, Grove RA, Brown R, Tompson D, Then Bergh F, Arnold DL.
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
J Neurol. 2016 Nov 25. [Epub ahead of print]
read
Khanfar MA, Affini A, Lutsenko K, Nikolic K, Butini S, Stark H.
Multiple Targeting Approaches on Histamine H3 Receptor Antagonists
Front Neurosci. 2016 May 30;10:201
read
Riddy DM, Cook A, Diepenhorst NA, Bosnyak S, Brady R, Mannoury-la-Cour C, Mocaer E, Summers RJ, Charman W, Sexton PM, Christopoulos A, Langmead CJ.
Isoform-specific biased agonism of histamine H3 receptor agonists.
Mol Pharmacol. 2016 Nov 18. pii: mol.116.106153. [Epub ahead of print]
read
Kim YS, Kim YB, Kim WB, Yoon BE, Shen FY, Lee SW, Soong TW, Han HC, Colwell CS, Lee CJ, Kim YI.
Histamine resets the circadian clock in the suprachiasmatic nucleus through the H1R-CaV 1.3-RyR pathway in the mouse.
Eur J Neurosci. 2015 Oct;42(7):2467-7
read
Uygun DS, Ye Z, Zecharia AY, Harding EC, Yu X, Yustos R, Vyssotski AL, Brickley SG, Franks NP, Wisden W.
Bottom-Up versus Top-Down Induction of Sleep by Zolpidem Acting on Histaminergic and Neocortex Neurons.
J Neurosci. 2016 Nov 2;36(44):11171-11184.
read
Benetti F, Furini CR, de Carvalho Myskiw J, Provensi G, Passani MB, Baldi E, Bucherelli C, Munari L, Izquierdo I, Blandina P.
Histamine in the basolateral amygdala promotes inhibitory avoidance learning independently of hippocampus.
Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2536-42.
read
Fabbri R, Furini CR Passani MB, Provensi G, Baldi E, Bucherelli C, Izquierdo I, de Carvalho Myskiw J, Blandina P.
Memory retrieval of inhibitory avoidance requires histamine H1 receptor activation in the hippocampus.
Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2714-20
read
Schneider EH1, Neumann D2, Seifert R2.
Modulation of behavior by the histaminergic system: lessons from H(1)R-and H(2)R-deficient mice.
Neurosci Biobehav Rev. 2014 May;42:252-66.
read
Schneider EH, Neumann D, Seifert R.
Modulation of behavior by the histaminergic system: lessons from HDC-, H3R- and H4R-deficient mice.
Neurosci Biobehav Rev. 2014 Nov;47:101-21
read
Provensi G, Blandina P, Passani MB.
The histaminergic system as a target for the prevention of obesity and metabolic syndrome.
Neuropharmacology. 2016 Jul;106:3-12
read
Kubo M, Kishi T, Matsunaga S, Iwata N.
Histamine H3 Receptor Antagonists for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
J Alzheimers Dis. 2015;48(3):667-71.
read
Thurmond RL, Greenspan A, Radziszewski W, Xu XL, Miao Y, Chen B2, Ge T, Zhou B, Baker D, Pavlova D, Ritchlin CT, Tanaka Y, Takeuchi T, Smolen JS.
Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies.
J Rheumatol. 2016 Sep;43(9):1637-42.
read
Levoin N, Labeeuw O, Billot X, Calmels T, Danvy D, Krief S, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M.
Discovery of nanomolar ligands with novel scaffolds for the histamine H4 receptor by virtual screening.
Eur J Med Chem. 2016 Sep 24;125:565-572
read
Nieto-Alamilla G, Márquez-Gómez R, García-Gálvez AM, Morales-Figueroa G, Arias-Montaño JA
The Histamine H3 Receptor: Structure, Pharmacology, and Function.
Mol Pharmacol. 2016 Nov;90(5):649-673
read
Mommert S, Ratz L, Herwig K, Rost M, Gutzmer R, Werfel T.
Genetic variations within the promotor region of the human histamine H4 receptor gene in psoriasis patients.
Pharmacol Res. 2016 Oct 7;114:121-127.
read
Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, Stark H, Thurmond RL, Haas HL.
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.
Pharmacol Rev. 2015 Jul;67(3):601-55
read
Kooistra A, Kuhne S, de Esch IJ, Leurs R, de Graaf C.
A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.
Br J Pharmacol. 2013 Sep;170(1):101-26
read
Birnkammer T, Spickenreither A, Brunskole I, Lopuch M, Kagermeier N, Bernhardt G, Dove S, Seifert R, Elz S, Buschauer A
The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H2 receptor agonists.
J Med Chem. 2012 Feb 9;55(3):1147-60
read
Tatsuro Shimamura, Mitsunori Shiroishi, Simone Weyand, Hirokazu Tsujimoto, Graeme Winter, Vsevolod Katritch, Ruben Abagyan, Vadim Cherezov, Wei Liu, Gye Won Han, Takuya Kobayashi, Raymond C. Stevens & So Iwata
Structure of the human histamine H1 receptor complex with doxepin
Nature 475,65-70 (07 July 2011)
read
Beaven MA.
Our perception of the mast cell from Paul Ehrlich to now.
Eur J Immunol. 2009 Jan 7;39(1):11-25.
read
Cowart MD, Altenbach RJ, Liu H, Hsieh GC, Drizin I, Milicic I, Miller TR, Witte DG, Wishart N, Fix-Stenzel SR, McPherson MJ, Adair RM, Wetter JM, Bettencourt BM, Marsh KC, Sullivan JP, Honore P, Esbenshade TA, Brioni JD.
Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.
J Med Chem. 2008 Oct 23;51(20):6547-57. Epub 2008 Sep 26.
read
van Rijn RM, van Marle A, Chazot PL, Langemeijer E, Qin Y, Shenton FC, Lim HD, Zuiderveld OP, Sansuk K, Dy M, Smit MJ, Tensen CP, Bakker RA, Leurs R.
Cloning and characterization of dominant negative splice variants of the human histamine H4 receptor.
Biochem J. 2008 Aug 15;414(1):121-31.
read
Saras A, Gisselmann G, Vogt-Eisele AK, Erlkamp KS, Kletke O, Pusch H, Hatt H.
Histamine action on vertebrate GABAA receptors: direct channel gating and potentiation of GABA responses.
J Biol Chem. 2008 Apr 18;283(16):10470-5. Epub 2008 Feb 15.
read